Nobel Biocare AB
PO Box 5190, 402 26
Västra Hamngatan 1
Göteborg
411 17
Sweden

23 FEB 2024

Notified Body Confirmation Letter

Reference: EU2023-607/793394

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Nobel Biocare AB
PO Box 5190, 402 26
Västra Hamngatan 1
Göteborg
411 17
Sweden
SRN Number: SE-MF-000000009

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,

Graeme Tunbridge

Graeme Tunbridge
Senior Vice President, Medical Devices

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

No. **CE 00353**

Issued To: **Nobel Biocare AB**
PO Box 5190, 402 26
Västra Hamngatan 1
Göteborg
411 17
Sweden

In respect of:

The design and manufacture of oral and extra-oral prosthetic reconstruction solutions, endosseous implants, abutments, other associated dental instruments and Surgical Kits.

Those aspects of Annex II related to metrology in the design and manufacture of software applications supporting oral, extra-oral and cranio-maxillofacial treatments.

Those aspects of Annex II concerned with metrological requirements of instruments and accessories for dental surgery

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex II excluding section 4. The quality assurance system meets the requirements of the directive. For the placing on the market of class III products an Annex II section 4 certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):

Gary E Slack, Senior Vice President - Medical Devices

First Issued: **1994-12-05** Date: **2019-10-31** Expiry Date: **2024-05-26**

...making excellence a habit.™